Video
Pharmacist Medication Insights: Fremanezumab-vfrm (Ajovy)
Author(s):
Fremanezumab-vfrm is the second FDA-approved preventive migraine treatment that works by blocking the activity of calcitonin gene-related peptide.
In 2018, the FDA approved fremanezumab-vfrm (Ajovy, Teva) for the preventive treatment of migraine in adults.
Fremanezumab-vfrm is the second FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule that is involved in migraine attacks. The first in this class, erenumab-aooe (Aimovig) was approved in 2018.
Migraine headache pain is often described by patients as an intense pulsing or throbbing pain in 1 area of the head. Additional symptoms include nausea and/or vomiting and sensitivity to light and sound. Migraine attacks can cause significant pain for hours to days, and can be so severe that the pain is disabling.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
